Elena Sharova

Mrs. Elena Sharova

FGBU FNKC PhChM FMBA Rossii
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ANAnastasia Nikitina
Anastasia Nikitina
ESElena Sharova
Elena Sharova
SDSvetlana A. Danilenko
Svetlana A. Danilenko
TBTatiana B. Butusova
Tatiana B. Butusova
AVAlexandr O. Vasiliev
Alexandr O. Vasiliev
EKElena S. Kostryukova
Elena S. Kostryukova
Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from russian patients

Verified
Journal Article
Open access
PDF file
VGVeronika Gordeeva
Veronika Gordeeva
ESElena Sharova
Elena Sharova
GAGeorgij Arapidi
Georgij Arapidi
Copy number variations (CNVs) are the predominant class of structural genomic variations involved in the processes of evolutionary adaptation, genomic disorders, and disease progression. Compared with single-nucleotide variants, there have been challenges associated with the detection of CNVs owing to their diverse sizes. However, the field has seen significant progress in the past 20–30 years. This has been made possible due to the rapid development of molecular diagnostic methods which ensure a more detailed view of the genome structure, further complemented by recent advances in computational methods. Here, we review the major approaches that have been used to routinely detect CNVs, ranging from cytogenetics to the latest sequencing technologies, and then cover their specific features.

Verified
Journal Article
Open access
PDF file
OLOlga Lebedeva
Olga Lebedeva
ESElena Sharova
Elena Sharova
DGDmitriy Grekhnev
Dmitriy Grekhnev
LSLiubov Olegovna Skorodumova
Liubov Olegovna Skorodumova
IKIrina Kopylova
Irina Kopylova
MLMaria A. Lagarkova
Maria A. Lagarkova
About 15% of patients with parkinsonism have a hereditary form of Parkinson’s disease (PD). Studies on the early stages of PD pathogenesis are challenging due to the lack of relevant models. The most promising ones are models based on dopaminergic neurons (DAns) differentiated from induced pluripotent stem cells (iPSCs) of patients with hereditary forms of PD. This work describes a highly efficient 2D protocol for obtaining DAns from iPSCs. The protocol is rather simple, comparable in efficiency with previously published protocols, and does not require viral vectors. The resulting neurons have a similar transcriptome profile to previously published data for neurons, and have a high level of maturity marker expression. The proportion of sensitive (SOX6+) DAns in the population calculated from the level of gene expression is higher than resistant (CALB+) DAns. Electrophysiological studies of the DAns confirmed their voltage sensitivity and showed that a mutation in the PARK8 gene is associated with enhanced store-operated calcium entry. The study of high-purity DAns differentiated from the iPSCs of patients with hereditary PD using this differentiation protocol will allow for investigators to combine various research methods, from patch clamp to omics technologies, and maximize information about cell function in normal and pathological conditions.

1 September 2020 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
EKElena Kotova
Elena Kotova
YSYulia A Savochkina
Yulia A Savochkina
YDYurii Doludin
Yurii Doludin
AVAlexander O Vasilyev
Alexander O Vasilyev
EPElena A Prilepskay
Elena A Prilepskay
ESElena Sharova
Elena Sharova
Purpose: Preclinical evaluation of PCA3 and AMACR transcript simultaneous detection in urine to diagnose clinical significant prostate cancer (prostate cancer with Gleason score ≥ 7) in a Russian cohort. Patients and Methods: We analyzed urine samples of patients with a total serum PSA ≥ 2 ng/mL: 31 men with prostate cancer scheduled for radical prostatectomy, 128 men scheduled for first diagnostic biopsy (prebiopsy cohort). PCA3, AMACR, PSA and GPI transcripts were detected by multiplex reverse transcription quantitative polymerase chain reaction, and the results were used for scores for calculation and statistical analysis. Results: There was no significant difference between clinically significant and nonsignificant prostate cancer PCA3 scores. However, there was a significant difference in the AMACR score (patients scheduled for radical prostatectomy p=0.0088, prebiopsy cohort p=0.029). We estimated AUCs, optimal cutoffs, sensitivities and specificities for PCa and csPCa detection in the prebiopsy cohort by tPSA, PCA3 score, PCPT Risk Calculator and classification models based on tPSA, PCA3 score and AMACR score. In the clinically significant prostate cancer ROC analysis, the PCA3 score AUC was 0.632 (95%CI: 0.511– 0.752), the AMACR score AUC was 0.711 (95%CI: 0.617– 0.806) and AUC of classification model based on the PCA3 score, the AMACR score and total PSA was 0.72 (95%CI: 0.58– 0.83). In addition, the correlation of the AMACR score with the ratio of total RNA and RNA of prostate cells in urine was shown (tau=0.347, p=6.542e– 09). Significant amounts of nonprostate RNA in urine may be a limitation for the AMACR score use. Conclusion: The AMACR score is a good predictor of clinically significant prostate cancer. Significant amounts of nonprostate RNA in urine may be a limitation for the AMACR score use. Evaluation of the AMACR score and classification models based on it for clinically significant prostate cancer detection with larger samples and a follow-up analysis is promising.

24 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TPTatiana petrova
Tatiana petrova
DKDaria V. Kuznetzova
Daria V. Kuznetzova
AKAlexandra V. Kanygina
Alexandra V. Kanygina
LSLiubov O. Skorodumova
Liubov O. Skorodumova
VIViktor A. Ivanov
Viktor A. Ivanov
ESElena Sharova
Elena Sharova
Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy and safety — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, established during ex vivo culture of a tumor specimen from a rectal cancer patient who was EBV-negative. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells ( r = 0.88) rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. Autologous TILs were negative for B cells and exhibited a strong interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214 or with the EBV peptide pool (1000–1800 spots per million of TILs). Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy even for EBV-negative patients.

1 November 2015 in Biomeditsinskaya Khimiya
Verified
Journal Article
Closed access
ANA.S. Nikitina
A.S. Nikitina
VBV.V. Babenko
V.V. Babenko
KBK.A. Babalyan
K.A. Babalyan
AVA.O. Vasiliev
A.O. Vasiliev
AGA.V. Govorov
A.V. Govorov
ESElena Sharova
Elena Sharova
The RNA-seq approach for prostate cancer candidate RNA biomarkers screening in plasma and urine obtained by minimally invasive or noninvasive methods is proved to be feasible. Significant amount of RNA biomarkers associated with prostate cancer according to the literature were found in plasma and urine samples obtained from patients with benign prostatic hyperplasia (BPH). The number of detected markers was shown to vary in accordance with method of library preparation used for transcriptome profiling. The detection of known RNA biomarkers for prostate cancer in urine and plasma samples shows the feasibility of such method for minimally invasive diagnostics. The fact of presence of the same RNA biomarkers in samples from patients with BPH suggests their possible lack of specificity and confirms the need for further research in this area.